The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Modifications of DNA by platinum complexes
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response
Gan, W. A. N. G., Dombkowski, A. A., CHUANG, L., & XU, X. X. S. (2004) · Cell Research · doi:10.1038/sj.cr.7290375 · Cited by 35
RetractedOxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., & Gerritsen, M. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21096 · Cited by 1,053
Signaling to Chromatin through Histone Modifications
Cheung, P., Allis, C. D., & Sassone-Corsi, P. (2000) · Cell · doi:10.1016/s0092-8674(00)00118-5 · Cited by 989
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Improved understanding in platinium antitumour chemistry
Reedijk, J. (1996) · Chemical Communications · doi:10.1039/cc9960000801 · Cited by 589
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi, S. P., Kurdi-Haidar, B., Gordon, R. T., Cenni, B., Zheng, H., Fink, D. A., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. A., et al. (1996) · PubMed · Cited by 502
Fuertes, M., Castilla, J., Alonso, C., & Pérez, J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368484 · Cited by 432
Molecular mechanisms involved in cisplatin cytotoxicity
Jordan, P., & Carmo-Fonseca*, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000762 · Cited by 398
Particular aspects of platinum compounds used at present in cancer treatment
Desoize, B., & Madoulet, C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00219-0 · Cited by 393
Curing metastatic testicular cancer
Einhorn, L. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072067999 · Cited by 387
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
Mann, S. C., Andrews, P. A., & Howell, S. B. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684878 · Cited by 349
Repair of Cisplatin−DNA Adducts by the Mammalian Excision Nuclease
Zamble, D. B., Mu, D., Reardon, J. T., Sancar, A., & Lippard, S. J. (1996) · Biochemistry · doi:10.1021/bi960453+ · Cited by 333
Selvakumaran, M., Pisarcik, D., Bao, R., Yeung, A. T., & Hamilton, T. C. (2003) · PubMed · Cited by 317
BCR/ABL Regulates Mammalian RecA Homologs, Resulting in Drug Resistance
Slupianek, A., Schmutte, C., Tombline, G., Nieborowska-Skorska, M., Hoser, G., Nowicki, M. O., Pierce, A. J., Fishel, R., & Skorski, T. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00357-4 · Cited by 314
Oxaliplatin-Induced Damage of Cellular DNA
Woynarowski, J. M., Faivre, S., Herzig, M. C. S., Arnett, B., Chapman, W. G., Trevino, A. V., Raymond, E., Chaney, S. G., Vaisman, A., Varchenko, M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12463-7 · Cited by 310
Drummond, J. T., Anthoney, A., Brown, R., & Modrich, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294
Reardon, J. T., Vaisman, A., Chaney, S. G., & Sancar, A. (1999) · PubMed · Cited by 281
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink, D. A., Zheng, H., Nebel, S., Norris, P. S., Aebi, S. P., Lin, T., Nehmé, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. (1997) · PubMed · Cited by 277
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage
Rubbi, C. P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg082 · Cited by 232
DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair
(2002) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(02)71040-4 · Cited by 230
Clinical Pharmacokinetics and Administration of Established Platinum Drugs
O??Dwyer, P. J., Stevenson, J. P., & Johnson, S. W. (2000) · Drugs · doi:10.2165/00003495-200059004-00003 · Cited by 217
Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models
Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Saito, M., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313709200 · Cited by 211
He, Q., Liang, C. H., & Lippard, S. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100108697 · Cited by 209
The importance of p53 location: nuclear or cytoplasmic zip code?
O’Brate, A., & Giannakakou, P. (2003) · Drug Resistance Updates · doi:10.1016/j.drup.2003.10.004 · Cited by 208
Spingler, B., Whittington, D. A., & Lippard, S. J. (2001) · Inorganic Chemistry · doi:10.1021/ic010790t · Cited by 207
Oxaliplatin: Pharmacokinetics and Chronopharmacological Aspects
L??vi, F., Metzger, G., Massari, C., & Milano, G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00001 · Cited by 194
Drug resistance and the microenvironment: nature and nurture
Morin, P. J. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00059-1 · Cited by 182
Ferreira, C. G., Tolis, C., & Giaccone, G. (1999) · Annals of Oncology · doi:10.1023/a:1008361818480 · Cited by 174
Kwon, J., Morshead, K. B., Guyon, J. R., Kingston, R. E., & Oettinger, M. A. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00102-7 · Cited by 166
Molecular aspects of resistance to antitumor platinum drugs
Brabec, V., & Kasparkova, J. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00047-x · Cited by 161
Self-citationMetal Antitumor Compounds: The Mechanism of Action of Platinum Complexes
Johnson, N. P., Butour, J.-L., Villani, G., Wimmer, F. L., Defais, M., Pierson, V., & Brabec, V. (1989) · Progress in Clinical Biochemistry and Medicine · doi:10.1007/978-3-642-74760-1_1 · Cited by 158
Self-citationThe dual role model for p53 in maintaining genomic integrity
Janus, F., Albrechtsen, N. J. W., Dornreiter, I., Wiesmüller, L., Große, F., & Deppert, W. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050266 · Cited by 154
NF-κB in cancer—a friend turned foe
Ravi, R. K., & Bedi, A. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.003 · Cited by 151
DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464
Kašpárková, J., Zehnulová, J., Farrell, N. P., & Brabec, V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208016200 · Cited by 147
Self-citationBlommaert, F. A., van Dijk-Knijnenburg, H. C. M., Dijt, F. J., Engelse, L. D., Baan, R. A., Berends, F., & Fichtinger-Schepman, A. M. J. (1995) · Biochemistry · doi:10.1021/bi00026a031 · Cited by 145
Inhibition of telomerase activity by cisplatin in human testicular cancer cells
Burger, A. M., Double, J. A., & Newell, D. R. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00521-7 · Cited by 141
Evidence for Involvement of HMGB1 Protein in Human DNA Mismatch Repair
Yuan, F., Gu, L., Guo, S., Wang, C., & Li, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401931200 · Cited by 140
Vaisman, A., Lim, S. E., Patrick, S. M., Copeland, W. C., Hinkle, D. C., Turchi, J. J., & Chaney, S. G. (1999) · Biochemistry · doi:10.1021/bi9909187 · Cited by 140
Stromal expression of c-Ets1 transcription factor correlates with tumor invasion.
Wernert, N., Gilles, F., Fafeur, V., Bouali, F., Raes, M., Pyke, C., Dupressoir, T., Seitz, G., Vandenbunder, B., & Stéhelin, D. (1994) · PubMed · Cited by 140
Wu, H. I., Brown, J. M., Dorie, M. J., Lazzeroni, L. C., & Brown, J. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3113 · Cited by 138
Span, P. N., Manders, P., Heuvel, J. J. T. M., Thomas, C. M. G., Bosch, R. R., Beex, L. V. A. M., & Sweep, F. C. G. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206040 · Cited by 137
Nehmé, A., Baskaran, R., Aebi, S. P., Fink, D. A., Nebel, S., Cenni, B., Wang, J. Y. J., Howell, S. B., & Christen, R. D. (1997) · PubMed · Cited by 129
Redon, S. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg259 · Cited by 125
Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human Cells
Papouli, E., Ćejka, P., & Jiricny, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0513 · Cited by 116
Farrell, N. P. (1993) · Cancer Investigation · doi:10.3109/07357909309011676 · Cited by 113
Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line
Pestell, K. E., Hobbs, S. M., Titley, J. C., Kèlland, L. R., & Walton, M. I. (2000) · Molecular Pharmacology · doi:10.1124/mol.57.3.503 · Cited by 113
Wu, F., Lin, X., Okuda, T., & Howell, S. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3942 · Cited by 111
Nehmé, A., Baskaran, R., Nebel, S., Fink, D. A., Howell, S. B., Wang, J. Y. J., & Christen, R. D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690176 · Cited by 111
Nucleotide Excision Repair from Site-Specifically Platinum-Modified Nucleosomes
Wang, D., Hara, R., Singh, G., Sancar, A., & Lippard, S. J. (2003) · Biochemistry · doi:10.1021/bi034264k · Cited by 107
Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R. D., & Howell, S. B. (2001) · PubMed · Cited by 106
Nováková, O., Kasparkova, J., Malina, J., Natile, G., & Brabec, V. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg863 · Cited by 105
Self-citationMutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA
Zdraveski, Z. Z., Mello, J. A., Farinelli, C. K., Essigmann, J. M., & Marinus, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105382200 · Cited by 103
Farrell, N. (1996) · PubMed · Cited by 102
Kerley-Hamilton, J. S., Pike, A. M., Li, N., DiRenzo, J., & Spinella, M. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208755 · Cited by 99
Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
Davidson, B., Reich, R., Goldberg, I., Gotlieb, W. H., Kopolovic, J., Berner, A., Ben‐Baruch, G., Bryne, M., & Nesland, J. M. (2001) · PubMed · Cited by 94
Binding of cis - and trans -dichlorodiammineplatinum(II) to the nucleosome core
Lippard, S. J., & Hoeschele, J. D. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.12.6091 · Cited by 93
Bergoglio, V., Canitrot, Y., Hogarth, L., Minto, L., Howell, S. B., Cazaux, C., & Hoffmann, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204743 · Cited by 92
Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
Mo, Y., Gan, Y., Song, S., Johnston, J. S., Xiao, X., Wientjes, M. G., & Au, J. L. ‐. (2003) · PubMed · Cited by 90
Zehnulová, J., Kašpárková, J., Farrell, N. P., & Brabec, V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103118200 · Cited by 81
Self-citationKašpárková, J., Nováková, O., Farrell, N. P., & Brabec, V. (2002) · Biochemistry · doi:10.1021/bi026614t · Cited by 78
Self-citationMasutomi, K., & Hahn, W. C. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00703-6 · Cited by 75
Spierings, D. C. J., de Vries, E. G. E., Vellenga, E., & de Jong, S. (2003) · The Journal of Pathology · doi:10.1002/path.1373 · Cited by 72
Role of PSO genes in repair of DNA damage of Saccharomyces cerevisiae
Brendel, M., Bonatto, D., Strauss, M., Revers, L. F., Pungartnik, C., Saffi, J., & Henriques, J. A. P. (2003) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2003.06.018 · Cited by 68
Recent insights into platinum drug resistance in cancer
Johnson, S. W., Ferry, K. V., & Hamilton, T. C. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80005-8 · Cited by 66
Wang, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh541 · Cited by 66
Beljanski, V., Marzilli, L. G., & Doetsch, P. W. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1496 · Cited by 66
Wu, X., Fan, W., Xu, S., & Zhou, Y. (2003) · PubMed · Cited by 62
Burstyn, J. N. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.21.4237 · Cited by 61
Cisplatin-induced Post-translational Modification of Histones H3 and H4
Wang, D., & Lippard, S. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402547200 · Cited by 60
Farrell, N. P., Povirk, L. F., Dange, Y., DeMasters, G. A., Gupta, M. S., Kohlhagen, G., Khan, Q. A., Pommier, Y. G., & Gewirtz, D. A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.023 · Cited by 57
Role of DNA mismatch repair in apoptotic responses to therapeutic agents
Meyers, M., Hwang, A., Wagner, M. W., & Boothman, D. A. (2004) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20056 · Cited by 57
Fourrier, L., Brooks, P., & Malinge, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301390200 · Cited by 57
Lan, L., Hayashi, T., Rabeya, R. M., Nakajima, S., Kanno, S., Takao, M., Matsunaga, T., Yoshino, M., Ichikawa, M., Riele, H. T., et al. (2003) · DNA repair · doi:10.1016/j.dnarep.2003.10.005 · Cited by 56
The interaction of cisplatin and analogues with DNA in reconstituted chromatin
Galea, A. M., & Murray, V. (2002) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(02)00535-3 · Cited by 56
Role of the transcription factor Ets-1 in cisplatin resistance
Wilson, A., Yamamoto, H., & Singh, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.823.3.7 · Cited by 52
Antitumor Active Trans-Platinum Compounds
Natile, G., & Coluccia, M. (2004) · CRC Press eBooks · doi:10.1201/b12414-7 · Cited by 46
Prolonged Wild-Type p53 Protein Accumulation and Cisplatin Resistance
Yazlovitskaya, E. M., DeHaan, R. D., & Persons, D. L. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4849 · Cited by 39
Kašpárková, J., Pospíšilová, Š., & Brabec, V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101224200 · Cited by 35
Self-citationTumor p53 status and response to topoisomerase II inhibitors
Valkov, N. I., & Sullivan, D. M. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00143-7 · Cited by 34
Tomohiro, T., Sawada, J.-I., Sawa, C., Nakura, H., Yoshida, S. M., Kodaka, M., Hatakeyama, M., Kawaguchi, H., Handa, H., & Okuno, H. (2002) · Bioconjugate Chemistry · doi:10.1021/bc015560h · Cited by 26
Furuta, M., Nozawa, K., Takemura, M., Izuta, S., Murate, T., Tsuchiya, M., Yoshida, K., Taka, N., Nimura, Y., & Yoshida, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11022 · Cited by 24
Kašpárková, J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh896 · Cited by 23
Mese, H., Ueyama, Y., Suzuki, A., Nakayama, S., Sasaki, A., Hamakawa, H., & Matsumura, T. (2001) · Chemotherapy · doi:10.1159/000048513 · Cited by 22
Interaction of cis-diamminedichloroplatinum (II) to chromatin
Foka, M., & Paoletti, J. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90425-9 · Cited by 21
cis-Diamminedichloroplatinum (II) modified chromatin and nucleosomal core particle
Hayes, J. J., & Scovell, W. M. (1991) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(91)90179-p · Cited by 21
Millard, J. T., & Wilkes, E. E. (2000) · Biochemistry · doi:10.1021/bi0022285 · Cited by 16
DNA modifying agents as tools for studying chromatin structure
Millard, J. (1996) · Biochimie · doi:10.1016/s0300-9084(97)84332-5 · Cited by 12
Telomerase inhibitors: a new option for chemotherapy
Chen, Z., & Corey, D. R. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)87173-7 · Cited by 11
Bubley, G. J., Teicher, B. A., Ogata, G. K., Sandoval, L. S., & Kusumoto, T. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90234-8 · Cited by 9
Cited by
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Brabec, V., & Nováková, O. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.05.002 · Cited by 384
Self-citation
Metadata
- Authors
- Brabec, V., & Kasparkova, J.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2005-06
- Volume
- 8
- Issue
- 3
- Pages
- 131-146
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W1242125470
- Cited by
- 373
- References
- 101
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.